CD274 and non-small cell lung carcinoma: These results led to the approval of specific immune checkpoint inhibitors (ICI) in certain cancer types, depending on the positivity of certain biomarkers (e.g., PD-L1 positivity in non-small cell lung cancer (NSCLC) for pembrolizumab treatment (Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.